机构：[1]The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.[2]Fujian Children's Hospital, Fuzhou, China.[3]Department of Oncology, Putian First Hospital, Putian, China.[4]Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.河南省肿瘤医院[5]Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.[6]Department of Cardiology, The People's Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong, Yunnan, China.[7]Department of Radiobiology, Fujian Medical University Cancer Hospital, Fuzhou, China.
Tumor antigen-induced lymphocyte transformation (LT) represents the antitumor cellular immunity, which might correlate with the cancer treatment outcome. Currently, there is no LT assay (LTA) routinely used in clinic. To establish a sensitive and convenient procedure for LTA, the same samples were used to simultaneously perform three assays: 5-ethynyl-2'-deoxyuridine (EdU) assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and carboxyfluorescein succinimidyl ester (CFSE) assay, and then the three results were compared. Several conditions were optimized: the LT harvest time, sources of lymphocytes (blood, lymph nodes, or spleen), the added amount of stimulatory tumor antigen and in vivo immunization priming time for LTA. The results of side-by-side comparison showed that (1) the 72 h for coculture of lymphocytes with tumor antigens was optimal time to harvest cells for LTA; (2) 50 μg/mL of tumor antigens was the optimal concentration for activation LT from three sources; (3) EdU incorporation was the sensitive and convenient assay for LTA as compared with MTT and CFSE assays; (4) the day 21-28 after in vivo priming immunization was the testing time for LTA; and (5) peripheral blood LT could be a good representative of whole body's lymphocyte reaction and practically easy cell source for LTA. This comparison of the three LTA in mouse model suggests that the EdU incorporation assay might be useful to evaluate the antitumor immunity stimulated by specific tumor vaccine or different anticancer therapies.
基金：
Fujian Development and Reform Commission (FGW2014)
to J.L.; Fujian Education Ministry (2013-58) and Fujian
Association for international exchange of personnel funds
(W13350000137) to L.Z.; Fujian Medical University
funds (0000-081919) to J.L.; and Fujian Key Laboratory of
Translational Cancer Medicine and Science and Technology
Program of Fujian Province, China (no. 2018Y2003).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区生物
小类|4 区生化与分子生物学4 区细胞生物学4 区遗传学
最新[2023]版：
大类|4 区生物学
小类|4 区生化与分子生物学4 区细胞生物学4 区遗传学
第一作者：
第一作者机构：[1]The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
通讯作者：
通讯机构：[1]The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.[7]Department of Radiobiology, Fujian Medical University Cancer Hospital, Fuzhou, China.[*1]The First Affiliated Hospital of Fujian Medical University Fuzhou 350005 China
推荐引用方式(GB/T 7714)：
Liu Jun,Liu Miao,Wang Jiling,et al.Comparison of Three Different Assays for the Detection of Tumor Antigen-Induced Lymphocyte Transformation In Vitro[J].DNA and cell biology.2019,38(11):1402-1410.doi:10.1089/dna.2019.4849.
APA：
Liu Jun,Liu Miao,Wang Jiling,Xu Weifeng,Lin Wanzun...&Zhang Lurong.(2019).Comparison of Three Different Assays for the Detection of Tumor Antigen-Induced Lymphocyte Transformation In Vitro.DNA and cell biology,38,(11)
MLA：
Liu Jun,et al."Comparison of Three Different Assays for the Detection of Tumor Antigen-Induced Lymphocyte Transformation In Vitro".DNA and cell biology 38..11(2019):1402-1410
